206258-93-7

Upstream product

• 3731-52-0 3-Aminomethylpyridine 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 

Downstream Products

• 206258-87-9 ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 206258-91-5 ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 223141-52-4 ethyl 7-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxylate 
• 206258-48-2 ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 161314-48-3 N-hydroxy-2-(4-methoxy-N-(pyridine-3-ylmethyl)phenylsulfonamido)acetamide 
• 206258-99-3 8-bromo-4-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-quinoline-3-carboxylic acid ethyl ester 
• 223141-50-2 ethyl 4-[(4-methoxy-benzenesulfonyl)pyridin-3-yl-methylamino]-3-methylisoxazolo[5,4-b]pyridine-5-carboxylate 
• 223141-48-8 ethyl 4-[(4-methoxybenzenesulfonyl)-pyridin-3-ylmethylamino]-3-methylisothiazolo[5,4-b] pyridine-5-carboxylate 
• 1027951-62-7 ethyl 2-(4-methyoxy-N-(pyridine-3-ylmethyl)phenylsulfonamido)acetate 
• 1000931-00-9 C₂₂H₂₂N₂O₅S 

Relevant academic research and scientific papers

Discovery of CGS 27023A, a non, peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits

Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

SULFONAMIDES

The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.